Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of ritlecitinib and brepocitinib in moderate to severe ulcerative colitis
2016-003708-29Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ritlecitinib tosilate, brepocitinib in autoimmune colitis, sponsored by Pfizer. Started Feb 2017; status: completed.
02
Drugs
ritlecitinib tosilatebrepocitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-003708-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003708-29.